

***Fiscal Year 2023 Department of Defense Military Burn Research Program (MBRP)
Reference Table of Award Mechanisms and Submission Requirements***

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadline |
|--|---|--|--|---|
| <p>Clinical Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-MBRP-CTRA</p> | <p>Investigators at all academic levels (or equivalent)</p> | <ul style="list-style-type: none"> • Intended to support human research projects that are likely to have a major impact on patient care by applying promising and well-founded research findings to the care of the burn-injured patient, particularly at the point of injury, or during the acute phase of injury. • Impact is a key component of this award mechanism and should be clearly described. • The proposed study must include clinical research, and may include initial proof-of-concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis. • Large randomized clinical trials are discouraged. • Preliminary data is required. • Animal research is not allowed. • <i>Pre-application submission is required; application submission is by invitation only</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.0 million for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Preproposal): May 31, 2023 5:00 p.m. Eastern time</p> <p>Application: September 5, 2023 11:59 p.m. Eastern time</p> |
| <p>Technology/Therapeutic Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-MBRP-TTDA</p> | <p>Investigators at all academic levels (or equivalent)</p> | <ul style="list-style-type: none"> • Intended to support the translation of promising preclinical findings into products for clinical applications. • Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. • Proof of concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established. • Preliminary data is required. • Clinical trials are not allowed. • <i>Pre-application submission is required; application submission is by invitation only.</i> | <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.0 million for total costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. | <p>Pre-Application (Preproposal): May 31, 2023 5:00 p.m. Eastern time</p> <p>Application: September 5, 2023 11:59 p.m. Eastern time</p> |